These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21852700)

  • 1. High yield of colorectal neoplasia detected by colonoscopy following a positive faecal occult blood test in the NHS Bowel Cancer Screening Programme.
    Lee TJ; Clifford GM; Rajasekhar P; Rutter MD; Kometa S; Ritchie MC; Waddup G; Nylander D; McNally RJ; Rees CJ
    J Med Screen; 2011; 18(2):82-6. PubMed ID: 21852700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimising faecal occult blood screening:retrospective analysis of NHS Bowel Cancer Screening data to improve the screening algorithm.
    Geraghty J; Butler P; Seaman H; Snowball J; Sarkar S; Blanks R; Halloran S; Bodger K; Rees CJ
    Br J Cancer; 2014 Nov; 111(11):2156-62. PubMed ID: 25225905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colonoscopy quality measures: experience from the NHS Bowel Cancer Screening Programme.
    Lee TJ; Rutter MD; Blanks RG; Moss SM; Goddard AF; Chilton A; Nickerson C; McNally RJ; Patnick J; Rees CJ
    Gut; 2012 Jul; 61(7):1050-7. PubMed ID: 21940723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symptoms do not predict colorectal cancer in an FOB screened population.
    Saldanha JD; Moug SJ; Linton K; Diament RH
    Scott Med J; 2013 May; 58(2):95-8. PubMed ID: 23728754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Faecal occult blood test-based screening programme with high compliance for colonoscopy has a strong clinical impact on colorectal cancer.
    Parente F; Marino B; DeVecchi N; Moretti R; ; Ucci G; Tricomi P; Armellino A; Redaelli L; Bargiggia S; Cristofori E; Masala E; Tortorella F; Gattinoni A; Odinolfi F; Pirola ME
    Br J Surg; 2009 May; 96(5):533-40. PubMed ID: 19358181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.
    Hardcastle JD; Chamberlain JO; Robinson MH; Moss SM; Amar SS; Balfour TW; James PD; Mangham CM
    Lancet; 1996 Nov; 348(9040):1472-7. PubMed ID: 8942775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin users attending for NHS bowel cancer screening have less colorectal neoplasia: chemoprevention or false-positive faecal occult blood testing?
    Lee TJ; Hull MA; Rajasekhar PT; Clifford GM; Ritchie M; James P; McNally RJ; Rutter MD; Rees CJ
    Digestion; 2012; 85(4):278-81. PubMed ID: 22538301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy.
    Greenberg PD; Bertario L; Gnauck R; Kronborg O; Hardcastle JD; Epstein MS; Sadowski D; Sudduth R; Zuckerman GR; Rockey DC
    Am J Gastroenterol; 2000 May; 95(5):1331-8. PubMed ID: 10811348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flexible sigmoidoscopy following a positive faecal occult blood test within a bowel screening programme may reduce the detection of neoplasia.
    Mansouri D; McMillan DC; Roxburgh CS; Moug SJ; Crighton EM; Horgan PG
    Colorectal Dis; 2013 Nov; 15(11):1375-81. PubMed ID: 23927751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology.
    Bampton PA; Sandford JJ; Cole SR; Smith A; Morcom J; Cadd B; Young GP
    Gut; 2005 Jun; 54(6):803-6. PubMed ID: 15888788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The positive predictive value of guaiac faecal occult blood test in relation to the number of positive squares in two consecutive rounds of colorectal cancer screening.
    Manfredi S; Philip J; Campillo B; Piette C; Durand G; Riou F; Bretagne JF
    Eur J Cancer Prev; 2011 Jul; 20(4):277-82. PubMed ID: 21633201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excellent performance of Hemoccult Sensa in organised colorectal cancer screening.
    Kershenbaum A; Flugelman A; Lejbkowicz F; Arad H; Rennert G
    Eur J Cancer; 2013 Mar; 49(4):923-30. PubMed ID: 23099005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The first 2 years of colorectal cancer screening in Ferrara, Italy.
    Matarese VG; Feo CV; Lanza G; Fusetti N; Carpanelli MC; Cataldo S; Cifalà V; Ferretti S; Gafà R; Marzola M; Montanari E; Palmonari C; Simone L; Trevisani L; Stockbrugger R; Gullini S
    Eur J Cancer Prev; 2011 May; 20(3):166-8. PubMed ID: 21445018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medications with anticoagulant properties increase the likelihood of a negative colonoscopy in faecal occult blood test population screening.
    Clarke P; Jack F; Carey FA; Steele RJ
    Colorectal Dis; 2006 Jun; 8(5):389-92. PubMed ID: 16684082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer?
    Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Niv Y
    Aliment Pharmacol Ther; 2006 Nov; 24(10):1475-81. PubMed ID: 17032281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An analysis of the duplicate testing strategy of an Irish immunochemical faecal occult blood test colorectal cancer screening programme.
    Kelley L; Swan N; Hughes DJ
    Colorectal Dis; 2013 Sep; 15(9):e512-21. PubMed ID: 23746062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening.
    Dekker N; van Rossum LG; Van Vugt-van Pinxteren M; van Stiphout SH; Hermens RP; van Zelst-Stams WA; van Oijen MG; Laheij RJ; Jansen JB; Hoogerbrugge N
    Eur J Cancer; 2011 Jul; 47(10):1571-7. PubMed ID: 21367600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early detection of colorectal cancer with faecal occult blood test screening.
    Paimela H; Malila N; Palva T; Hakulinen T; Vertio H; Järvinen H
    Br J Surg; 2010 Oct; 97(10):1567-71. PubMed ID: 20603855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Repeat mass screening for fecal occult blood for the diagnosis of colorectal neoplasms in a rural district. Results of an informational campaign].
    Hofbauer F; Mach K; Egermann G
    Wien Klin Wochenschr; 1991; 103(10):288-95. PubMed ID: 1858377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colorectal cancer screening through detection of fecal occult blood in a controlled health zone.
    Tárraga P; García-Olmo D; Celada A; García-Molinero Mf; Divison JA; Casado C
    Rev Esp Enferm Dig; 1999 May; 91(5):335-44. PubMed ID: 10362875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.